DUAL BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE
Abstract
Background: Inflammatory bowel diseases are increasingly common conditions occurring mainly in young people. The etiology of these diseases is not fully understood, so the treatment of choice is mainly conservative. The main target is to achieve and sustain clinical and endoscopic glucocorticosteroid-free remission.
Purpose: The purpose of this study is to describe the non-standard use of dual biological therapy in selected groups of patients who have lost secondary response to treatment.
Description: This article discusses two cases of patients suffering from ulcerative colitis and Crohn's disease. During standard therapy, disease exacerbations and secondary loss of response to biologic drugs were observed. The combination of two biologic drugs resulted in remission of the disease and improvement in the patient's clinical condition.
Conclusions: Dual biologic therapy may show promise in the treatment of inflammatory bowel disease in selected groups of patients. Combining different mechanisms of action of drugs allows for comprehensive control of inflammation, increasing the effectiveness of treatment.
References
Guo M, Wang X. Pathological mechanism and targeted drugs of ulcerative colitis: a review. Medicine (Baltimore). 2023 Sep 15;102(37):e35020. doi:10.1097/MD.0000000000035020. PMID: 37713856; PMCID: PMC10508406.
Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, et al. Guidelines of the Polish Society of Gastroenterology and the National Consultant in Gastroenterology for the management of patients with Crohn's disease. Gastroenterol Rev. 2021;16(4):257-96.
Eder P, Łodyga M, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, et al. Guidelines of the Polish Society of Gastroenterology and the National Consultant in Gastroenterology on the management of patients with ulcerative colitis. Gastroenterol Rev. 2023;18(1):1-42.
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr;106(4):685-98. doi:10.1038/ajg.2011.103. PMID: 21427713.
Lorinczy K, Miheller P, Kiss SL, Lakatos PL. A biológiai kezelés során bekövetkező hatásvesztés gyakorisága, okai és klinikai megközelítése gyulladásos bélbetegségek esetén [Epidemiology, predictors and clinical aspects of loss of response to biological therapy]. Orv Hetil. 2012 Feb 5;153(5):163-73. doi:10.1556/OH.2012.29294. PMID: 22275731. [Hungarian]
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52-65.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004 Mar 4;350(9):876-85.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 5;357(3):239-50.
Baert F, Noman M, Vermeire S, Van Assche G, Gornet JM, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003 Feb 13;348(7):601-8.
Pękala A, Filip R, Aebisher D. Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: a prospective cohort study. J Clin Med. 2021 Jun 16;10(12):2653. doi:10.3390/jcm10122653. PMID: 34208676; PMCID: PMC8235171.
Views:
7
Downloads:
6
Copyright (c) 2025 Aleksandra Karnas, Gabriela Majka, Karol Bednarz, Piotr Pitrus, Anita Krowiak, Magdalena Kowalczyk, Karolina Krowiak, Anita Warzocha, Wiktoria Hander, Maria Jasiewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
